17 October 2017
News and Views
Links and Services
November's issue of the Alimentary Pharmacology & Therapeutics evaluates the outcome of infliximab dose doubling in patients with ulcerative colitis after loss of response to infliximab.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors